News

Amgen's migraine drug shows promise in Phase II


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Amgen's migraine drug shows promise in Phase II


Date: 15/05/2015


First data from a mid-stage trial assessing Amgen’s fully human monoclonal antibody AMG 334 show the drug to be effective in preventing migraine, one of the world’s top 10 most debilitating conditions affecting more than 10% of the population. 

The global, double-blind, Phase II study met its primary endpoint by showing that AMG 334 significantly reduced monthly mean migraine days compared with placebo.

For more click here

Source: Pharma Times

© Catalyst Innovation Portal 2019